Business
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- 2025 net product sales of $521 million\n\n\n- 2026 expected global net product sales of $630 million to $650 million\n\n\n- Volixibat VISTAS study in PSC topline data expected Q2 2026\n\n\n- LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026\n\n\n- Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026\n\n\n- Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update.\n\n\n“2025 was a year of meaningful progress and execution for Mirum, setting the stage for a pivotal 2026,” said Chris Peetz, Chief Executive Officer of Mirum. “With the recent addition of brelovitug in HDV, we now expect four potentially registrational readouts over the next 18 months, beginning with topline results from the VISTAS study in PSC in the second quarter. This catalyst-rich period, combined with continued commercial performance and financial discipline, positions us well to deliver for shareholders and patients.”\n\n\n2026 Expectations and Milestones: Commercial Growth and Pipeline Advancement\n\n\n\n2026 guidance: expect global net product sales of approximately $630 million to $650 million.\n\n\n\nVolixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected in Q2 2026.\n\n\n\nLIVMARLI EXPAND Phase 3 study for pruritus in additional rare cholestatic conditions expected to complete enrollment H1 2026; topline data expected in Q4 2026.\n\n\n\nVolixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in H2 2026.\n\n\n\nBrelovitug AZURE-1 study in chronic hepatitis delta virus (HDV) interim data expected in Q2 2026; topline data from AZURE-1 and AZURE-4 expected in H2 2026.\n\n\n\n2025 and Recent Highlights\n\n\nCommercial: Accelerating Global Rare Disease Impact\n\n\n\n2025 total net product sales of $521.3 million.\n\n\n\n2025 LIVMARLI net product sales totaled $360.0 million, including $244.7 million in U.S. net product sales, representing 69% year-over-year growth from 2024 net product sales.\n\n\n\n2025 Bile Acid Medicines net product sales totaled $161.3 million rep...